This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
This Cooperative Agreement award is funded by the Advanced Research Projects Agency for Health (ARPA-H), a program under the Department of Health and Human Services' National Institutes of Health (CFDA 93.384). The goal of the $62.5M award is to develop a broadly protective vaccine against emergent alphaviruses, which cause neurological and rheumatic diseases and pose substantial risks to human health. The key products and services to be delivered include: Designing and testing novel...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This $5.25 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at The Wistar Institute of Anatomy and Biology to develop a universal coronavirus vaccine utilizing nucleic acid delivered nanoparticles. The grant period runs from September 2022 through August 2025. Under the award, Wistar Institute researchers will manipulate variables such as antigen epitope diversity, density, valency, duration of antigen...
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...
This Cooperative Agreement award from the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H) program, CFDA #93.384, provides $59,956,646 to develop machine learning-enabled approaches for designing universal vaccines against herpesviruses. The University of Washington (UW) leads this multidisciplinary program, collaborating with researchers at the University of Texas at Austin and Dartmouth College to leverage AI and computational methods for engineering...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,178,000.00 to develop a "tunable nanophage platform" for rapidly screening and evaluating potential vaccine candidates against emerging infectious diseases, including coronaviruses. The key products and services to be delivered include: Engineering "second generation" nanophages that display...
The federal Cooperative Agreement award titled "SCIENTIFIC PLATFORM FOR HIGH EFFICACY ANTIGEN DESIGN VIA ROBUST INTEGRATION OF COMPUTATIONAL EXPERIMENTS, AI, AND PROTEIN MODELING (SPHERICAL)" was awarded by the National Institutes of Health (NIH) under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384). The $26,679,771 award to the Texas A&M Engineering Experiment Station (Tees) will support the development of a scientific platform that integrates...
This Project Grant award of $709,236 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a nanoparticle-based adjuvant formulation containing a TLR7 agonist to overcome immunodominance and induce broad antibody responses against the influenza virus. The primary research goals are to: 1) Determine how the TLR7 nanoparticle adjuvant impacts immunodominance, breadth, and tolerance across...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...